Marta Agostinho
LightNews LightNews
meagostinho.bsky.social
Marta Agostinho
@meagostinho.bsky.social
79 followers 36 following 9 posts
Executive Director @eu-life.bsky.social. Scientist dedicated to the interface of science with policy. #research #sciencepolicy Sharing her personal views.
Posts Replies Media Videos
Reposted by Marta Agostinho
eu-life.bsky.social
Today we feature Isabel Vercauteren, CEO & Co-founder at Aphea.bio, a science-driven company that creates natural solutions that serve as effective alternatives to chemical pesticides & synthetic fertilizers.

#FundamentalResearch for #EUcompetitiveness
EU-LIFE #innovation ➡️ eu-life.eu/innovation
"Discovery driven research is vital for innovation as it provides new knowledge and insights needed to develop transformative solutions. With that spirit of innovation, Aphea.Bio creates natural solutions based on microbiology that serve as effective alternatives to chemical pesticides and synthetic fertilizers," said Isabel Vercauteren.
March 6, 2025 at 7:50 AM
Reposted by Marta Agostinho
eu-life.bsky.social
Today we feature @ritabg.bsky.social, CEO #MunaTherapeutics (Denmark, Belgium & US), a company that develops #therapies that slow or stop devastating neurodegenerative diseases incl. #Alzheimer’s & #Parkinson’s

#FundamentalResearch for #EUcompetitiveness

EU-LIFE #innovation ➡️ eu-life.eu/innovation
“Muna Therapeutics, a biotech company based in Denmark, Belgium and the US, discovers and develops medicines that protect the brain and slow or stop the progression of neurodegenerative diseases, which affect cognition, behavior and quality of life for millions of patients and their loved ones around the globe. Muna’s most advanced potential medicine for Alzheimer’s disease was enabled by more than 25 years of discovery-led research conducted by scientists and clinicians across the EU and around the globe, and will be in human safety testing in 2025,” said Rita Balice-Gordon, CEO Muna Therapeutics.
February 25, 2025 at 8:20 AM
Reposted by Marta Agostinho
eu-life.bsky.social
Today we feature Sergio Abrignani, Co-founder and Member of the Board of Directors of #CheckmAb (Italy), a company that develops monoclonal #antibodies against Treg cells present in diseased tissues as tools for safer and efficacious immunotherapies against #cancer and autoimmune diseases.
"Fundamental research uncovers new knowledge and fuels innovation, laying the groundwork for state-of-the-art technologies. It is the main tool for innovators to drive changes across industries and for companies to stay competitive by developing disruptive ideas and/or products," said Sergio Abrignani, CheckmAb
February 20, 2025 at 8:32 AM
meagostinho.bsky.social
Welcome!!
February 18, 2025 at 3:38 PM